> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# CGMP Violations in Premier Nutra Pharma Inspection
- URL: https://www.fdaweb.com/cgmp-violations-in-premier-nutra-pharma-inspection/
- Published: 2023-05-09T12:00:00.000Z
- Updated: 2026-09-14T18:30:36.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5154399

A 7/5-7/8/22 FDA inspection at Premier Nutra Pharma, in Carlsbad, CA, found significant violations of current good manufacturing practice (CGMP) regulations for finished drugs. A just-released 12/9/22 Warning Letter says specific violations were:

- failing to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch had already been distributed;
- failing to establish and follow appropriate written procedures designed to prevent objectionable microorganisms in drug products not required to be sterile;
- failing to prepare batch production and control records with complete information relating to the production and control of each batch of drug product produced; and
- failing to establish an adequate quality unit and to have in writing and fully followed the responsibilities and procedures applicable to the quality control unit.

FDA reminded Premier that it is responsible for the quality of drugs it produces as a contract manufacturer regardless of agreements in place with product owners. The agency recommended that the company retain a qualified consultant to assist it in meeting CGMP requirements.

Premier was told to correct the violations promptly and to respond with a list of specific steps it has taken to address violations and prevent their recurrence, with a schedule for completing the corrections.